Alexey V. Danilov
- Janssen Research and Development, L.L.C.
Randomized, double-blind, placebo-controlled Phase 3 study of Ibrutinib, a Bruton`s Tyrosine Kinase (BTK) inhibitor, in combination with Bendamustine and Rituximab (BR)in subjects with relapsed or refractory chronic lymphocytic leukemia/smallLymphocytic lymphoma
Immunology and Cancer Immunotherapy
- Prometheus Laboratories Incorporated, Cytokine Working Group (CWG)
Inhibiting the systemic autophagic syndrome - A Phase I/II study of hydroxychloroquine and aldesleukin in Renal Cell Carcinoma patients (RCC)